Merck Adds To Phase III Pipeline With Lundbeck Sleep-Aid Gaboxadol

Merck's $270 mil. licensing deal for Lundbeck's Phase III sleep disorder agent gaboxadol could give Merck a fifth new product approval around the time that Zocor comes off patent

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet